Apr 28, 2021 7:30am EDT Matinas BioPharma to Participate in 7th Annual Truist Securities Life Sciences Summit
Apr 27, 2021 7:30am EDT Matinas BioPharma to Webcast Conference Call Discussing First Quarter 2021 Financial and Operational Results on May 10, 2021
Mar 29, 2021 6:30am EDT Matinas BioPharma Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights
Mar 15, 2021 7:00am EDT Matinas BioPharma to Webcast Conference Call Discussing Fourth Quarter and Full Year 2020 Financial and Operational Results on March 29, 2021
Feb 01, 2021 6:00am EST Matinas BioPharma Announces Topline Results from ENHANCE-IT Study of LYPDISO™ Against Vascepa®
Jan 04, 2021 7:00am EST Matinas BioPharma Announces FDA Conditional Acceptance of LYPDISO™ as the Brand Name for MAT9001
Dec 07, 2020 6:35am EST Matinas BioPharma Announces Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate Oral Formulations of Gilead’s Antiviral Remdesivir Utilizing Matinas’ LNC Platform Delivery Technology
